Adult Immunization

Moderna's investigational vaccine against RSV in adults showed mean efficacy of 83% against the infection and is the only mRNA technology-based RSV shot.

If approved the 21-valent shot would be the first pneumococcal conjugate vaccine indicated specifically for adults.

First-ever vaccines against RSV in older adults, from GSK and Pfizer, won FDA approval in 2023. This brief slide show highlights the year's headline news about both.

Your daily dose of the clinical news you may have missed.

With 3 vaccines approved against pneumococcal disease in adults, is there really the need - or the room - for 1 more? Here's what one physician thinks.

The vaccine has been available in Europe for more than 20 years; the ACIP published recommendations in November. Will any of your patients need it?

The coadministration of RSVpreF and seasonal influenza vaccine was found to generate robust immune responses in older adults, reported authors of new study.

Should the monovalent COVID-19 vaccine approved for use this respiratory virus season be given universally or to only those at high risk? There are differences of opinion.

Physician author Terry Brenneman, MD, suggests a key difference between a great clinician and an average one, and it has to do with used car sales. Read more.

Your daily dose of the clinical news you may have missed.

The comparable immune responses were observed in 50-to 59-year-olds at high risk of RSV-LRTD as well as a wider group at average risk, according to preliminary phase 3 data.

The investigational combination vaccine against influenza and SARS-CoV-2 proved both safe and effective in recent results from a phase 1/2 trial, said Moderna.

IDWeek was packed with so much new science it was hard to make choices. Here we topline 10 with outcomes of interest to primary care, ICYMI.

Reasons for not getting a COVID-19 booster ranged from worry about taking time off to believing it won't add any additional protection from infection.

AAFP president-elect Steven Furr, MD, offers 3 thoughts on maximizing opportunities this year to give all necessary vaccines.

Furr on COVID-19 shot: The expectation that 90% of the US population would take this new vaccine that they'd never heard of was probably not practical.

The combination was found equally as effective as 2 standard influenza vaccine comparators and as the Moderna Spikevax COVID-19 booster shot.

The pair of scientists was cited "for their discoveries concerning nucleoside base modifications that enabled the development of effective mRNA vaccines against COVID-19."

Moderna reported at its annual R&D day that its flu vaccine has met primary phase 3 endpoints and that phase 1/2 data show higher HIA titers vs Fluzone HD.

"Keep the vaccination conversation going this year, even though your patients, and probably you, too, have grown tired of the issues and your team is worn out."

SARS-CoV-2, influenza, and respiratory syncytial virus are all targets this flu season for family physician Chuck Vega, MD, who says he's "going for all 3."

RSV is comparable to influenza every year in the severity of infection among older adults. Drs Bill Schaffner and Chuck Vega say both patients and clinicians will need education this season.

As flu season approaches this year, experts stress that it's not just about influenza anymore; they discuss testing, antiviral treatment, and management of coinfection.

Well-known ID specialist Bill Schaffner, MD, and active primary care educator Chuck Vega, MD, offer thoughts on how to get shots into arms in the 2023-2024 respiratory virus season.

Respiratory virus season 2023-2024 will likely be a "transition year," according to family physician Chuck Vega, MD and ID specialist Bill Schaffner, MD. Here's why.